Plain-English translation of NCT06570291 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a treatment called AlloJoin®, which uses special cells (called ) taken from donated fat tissue. These cells are injected directly into the knee to help reduce arthritis pain and improve how well your knee works. Researchers want to see if this treatment is safe and works better than a standard comparison treatment.
Knee osteoarthritis causes pain and stiffness that can limit daily activities, and current treatments don't work for everyone. This trial exists to see whether this new stem cell treatment can offer people with moderate knee arthritis a better option to ease pain and restore movement.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the stem cell injection or a standard comparison injection into your knee. You'll have clinic visits to receive the treatment and to have your knee pain and function checked over time. The study involves X-rays and questionnaires about your pain and how well your knee is working. You should expect follow-up visits to monitor how you're doing with the treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Wuxi Cellular Biopharmaceutical Group Ltd.
Enrollment target
~520 participants
Started
February 2025
Primary completion
December 2026
Age range
40 Years – 75 Years
Last updated on clinicaltrials.gov in July 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.